💸 The Tape

The cannabis sector is still navigating a landscape that's equal parts budding opportunity and thorny regulation. Last week, three multi-state operators (MSOs)—Green Thumb Industries (GTI), Curaleaf Holdings, and Trulieve Cannabis—dropped their Q4 and full-year 2025 earnings, offering a fresh snapshot of an industry grappling with price compression, expansion dreams, and the eternal wait for federal reform. Think of these reports as a financial strain review: potent in some areas, a bit harsh in others.

In this edition, we'll unpack each company's performance with a mildly witty yet professional lens—because who says analyzing balance sheets can't have a little buzz? Then, we'll treat their metrics as a collective dataset, comparing and contrasting revenues, margins, cash flows, and more. Spoiler: Trulieve flexes on gross margins like it's hoarding all the top-shelf flower, while Curaleaf's international flair adds a worldly twist. GTI? They're the steady grower in the bunch. Let's roll into the details.

Green Thumb Industries: Steady Growth Amid the Squeeze

Green Thumb Industries, the Chicago-based operator known for its RISE dispensaries and RYTHM brand, wrapped up 2025 with a performance that's as reliable as a well-cured joint—consistent, if not explosive. For the full year, revenue climbed 3.4% to $1.2 billion, a modest uptick in a market where prices have been tumbling faster than a novice on edibles. Q4 shone brighter, with revenue hitting $311.1 million, up 5.7% year-over-year (YoY), thanks in part to adult-use launches in Minnesota and solid showings in Ohio, Florida, and New York.

Gross profit for the year came in at $574.9 million, yielding a 48.9% margin—down from 52.9% in 2024, a victim of that pesky price compression. Q4 margins dipped further to 45.4%, reflecting the industry's competitive grind. On the bright side, GAAP net income flipped positive at $114.2 million for the year ($0.49 per basic share), a stark improvement from $73.1 million in 2024, bolstered by a $125.9 million fair value adjustment in Q4. That quarter alone delivered $83.2 million in net income, or $0.36 per basic share.

Adjusted EBITDA (which we'll use for apples-to-apples comparisons, stripping out one-offs) stood at $348.4 million for the year (29.6% margin), down slightly from $371.3 million in 2024. Q4 normalized EBITDA edged up to $100.2 million (32.2% margin). Cash flow from operations was a robust $294.9 million annually, with $90 million in Q4, leaving GTI with $274.3 million in cash at year-end. Debt? A manageable $244.9 million, and they even repurchased shares equivalent to 7.7 million subordinate voting shares for $38.9 million.

Operationally, GTI expanded to 113 stores across 14 states, adding 12 locations in 2025. Brands like RYTHM claimed top spots—#1 flower brand per BDSA data—and events like the Bud Ball concert series engaged thousands. Management, led by CEO Ben Kovler, touted their "durable model" and balance sheet strength, while President Anthony Georgiadis highlighted retail growth and capital returns. Looking ahead, they expect Q1 2026 revenue to dip mid-single digits sequentially due to seasonality and pricing woes, with capex steady at ~$80 million.

In short, GTI's report reads like a balanced hybrid: not the highest yield, but resilient and cash-generative. They're positioning for adult-use expansions without overextending—smart in a sector where overambition can lead to a bad trip.

Curaleaf Holdings: International Ambitions and Margin Magic

Curaleaf, the Stamford, Connecticut powerhouse with a footprint spanning the U.S. and Europe, delivered a report that's globally minded but domestically challenged. Full-year revenue slipped to $1.268 billion from $1.334 billion in 2024, a ~5% decline, dragged by U.S. price wars despite a whopping 63% international growth to $172.5 million. Q4 bucked the trend, with revenue up 2% YoY to $333.1 million—their strongest in six quarters—and 5% sequentially, fueled by international sales hitting $50.7 million.

Gross profit impressed at $631 million for the year (50% margin, up 150 basis points YoY on an adjusted basis), with Q4 at $161.8 million (49% margin, up 60 basis points). Yet, the bottom line stung: a $201.9 million net loss from continuing operations ($0.26 per share), improved slightly from $211.6 million in 2024. Q4 net loss was $49.3 million ($0.06 per share). Adjusted EBITDA landed at $274.7 million annually (21.7% margin, down from 22.7%), with Q4 at $69 million (20.7% margin, down 250 basis points).

Cash flows showed grit: $152 million from operations for the year ($42 million in Q4), generating $89.3 million in free cash flow after $63.4 million capex. Year-end cash was $101.6 million, the lowest among the trio, with net debt at $548.7 million—higher leverage reflecting their acquisition-heavy past. Balance sheet totals: $2.845 billion in assets, weighed by $1.011 billion in intangibles and $635 million goodwill.

On the ops front, Curaleaf ended with 161 dispensaries (up from 159 in Q3), adding spots in Florida and Maine. Innovations included Anthem Bold pre-rolls and a medically certified inhalation device in the UK/Germany. Per Hoodie Analytics, they snagged #1 market share in their portfolio and top vape brand status for Select. CEO Boris Jordan celebrated the "Return to Our Roots" plan's completion and a $500 million debt offering, signaling a shift to "Built for Growth" with focus on cultivation, merchandising, and acquisitions. No hard guidance, but expect organic acceleration.

Curaleaf's vibe? An ambitious sativa: expansive reach (especially abroad), improving margins, but higher debt and U.S. revenue dips suggest they need to prune costs to truly flourish.

Trulieve Cannabis: Margin Masters with Cash Flow Crown

Tallahassee's Trulieve, the Florida-centric giant, posted a report that's all about efficiency—like a perfectly trimmed bud maximizing potency. Full-year revenue held flat at $1.181 billion, a feat amid pricing pressures, with 94% from retail. Q4 revenue dipped 3% YoY to $293 million but rose 2% sequentially.

Where Trulieve shines: gross profit of $711 million annually (60% margin, steady YoY), with Q4 at $175 million (also 60%). That's the highest margin in the group—kudos to operational efficiencies and promo discipline. Net loss narrowed to $116 million for the year ($43 million in Q4), from $155 million in 2024. Adjusted, it's a $27 million loss annually ($3 million in Q4). Adjusted EBITDA hit a record $427 million (36% margin, up 2% YoY), with Q4 at $105 million (36%).

Cash kingpin status: Record $273 million from operations ($59 million Q4), yielding $229 million free cash flow. Year-end cash: $256 million, up from 2024. Debt management was aggressive, redeeming $368 million in notes, leaving ~$232 million outstanding (inferred from prior data; report focuses on reductions). Balance sheet: $2.696 billion assets, $1.553 billion liabilities.

Operationally, Trulieve boasts 233 stores (now 234), adding 11 in 2025, plus a Texas license win. Sold a record 50.1 million branded units (up 5%), grew rewards to 915,000 members, and launched a Florida app. CEO Kim Rivers highlighted debt repositioning and momentum into 2026, eyeing federal rescheduling and state expansions like Florida and Texas. No specific numbers, but they target "accelerated growth" via hubs.

Trulieve's essence: A robust indica—strong margins, cash generation, but flat revenue signals a need for geographic diversification beyond Florida's sunny confines.

Comparing the Trio: A Data-Driven Showdown

Now, let's treat these earnings as a dataset, slicing and dicing metrics to reveal patterns. In a sector where average wholesale prices fell double-digits for the third year, these MSOs showcase divergent strategies: GTI's balanced U.S. focus, Curaleaf's global bet, Trulieve's efficiency edge. We'll use tables for clarity, focusing on full-year and Q4 2025 figures (all in USD millions unless noted).

Revenue and Growth: Who's Expanding the Patch?

All three hover around $1.2 billion annually, but trajectories differ. GTI eked out growth; Curaleaf slid on U.S. woes but surged internationally; Trulieve stayed steady.

Curaleaf leads Q4 revenue, but their annual dip highlights U.S. vulnerability—domestic sales fell while international jumped 63%. GTI's growth came from new stores and adult-use markets; Trulieve's flatline reflects Florida dominance (over 50% of ops) amid competition. Witty take: Curaleaf's like the world traveler racking up miles, while Trulieve sticks to its home grow.

Profitability: Margins Under the Microscope

Trulieve crushes on gross margins, thanks to vertical integration and cost control. Adjusted EBITDA tells a similar tale.

Contrast: Trulieve's 60% margin is envy-inducing, offsetting flat revenue for top EBITDA. Curaleaf improved margins via productivity but lags on EBITDA due to higher SG&A (international ops aren't cheap). GTI's dip reflects price wars but stays competitive. If margins were THC levels, Trulieve's would have you couch-locked in profitability.

Bottom Line and Cash: Who’s Banking the Green?

Net results vary wildly—GTI profitable, others in the red—but cash flows reveal health.

GTI's profit boost from adjustments masks underlying pressures, but their cash hoard and flows scream stability. Trulieve's record flows fund debt paydowns ($368 million redeemed). Curaleaf's lower cash and higher debt (post-$500 million raise) suggest leverage risks, though flows improved. Pro tip: In cannabis, cash is king—GTI and Trulieve wear the crown, while Curaleaf plays catch-up.

Balance Sheet Strength: Roots and Resilience

Assets and liabilities highlight scale:

All boast ~$2.7-2.8 billion assets, but Curaleaf's lower equity reflects losses and intangibles from acquisitions. GTI's equity lead signals shareholder value; Trulieve's debt reductions bolster resilience. Forward capex: GTI ~$80 million in 2026; Trulieve eyes growth initiatives without specifics.

Operational contrasts: GTI and Curaleaf emphasize brands (RYTHM #1 flower; Select #1 vape); Trulieve touts units sold (50M+). All battle price compression but invest in adult-use (e.g., Minnesota for GTI, Ohio for Trulieve). International? Curaleaf's edge (17% of revenue) vs. negligible for others.

Wrapping Up: Budding Prospects in a Cloudy Market

As we compare these datasets, patterns emerge: Trulieve's efficiency makes it the margin maestro, ideal for a mature market; Curaleaf's global push offers diversification but at a cost; GTI strikes a Goldilocks balance—growth without excess risk. Collectively, they generated ~$3.65 billion in revenue, underscoring MSOs' scale amid fragmentation. Yet, with federal rescheduling looming, these reports hint at pent-up potential: safer banking, uplisting, and state expansions could supercharge all three.

In a witty nod, if cannabis earnings were strains: GTI's "Balanced Buzz," Curaleaf's "Worldly Wanderer," Trulieve's "Efficiency Express." For investors, the takeaway? Bet on cash-rich operators with strong roots—they'll weather the regulatory winter. Until next time, stay elevated and informed.

🗞️ The News

📺 YouTube

Federal Hemp Ban: What’s Actually Targeted? | TDR Cannabis in 5

What we will cover:

✅ In the latest TDR Cannabis in Five, host Shadd Dales breaks down Congress’ move to ban intoxicating hemp products — and why the conversation online has become so divided.

Lawmakers are targeting products like THCA flower, Delta-8, Delta-10, HHC, and other lab-converted cannabinoids that emerged from the 2018 Farm Bill hemp loophole. That loophole defined hemp by pre-decarboxylation THC levels, allowing THCA flower to be sold legally even though it converts to THC when heated.

But the concern now isn’t just about intoxicating hemp.

The federal language being proposed could unintentionally impact:
Full-spectrum CBD products
20:1 CBD:THC formulations similar to Charlotte’s Web
Hemp genetics and seed sales
Non-intoxicating cannabinoid products